Praxis Precision Medicines Reports 53% Seizure Reduction With Relutrigine in EMBOLD Study
Reuters
Dec 08
<a href="https://laohu8.com/S/PRAX">Praxis Precision Medicines</a> Reports 53% Seizure Reduction With Relutrigine in EMBOLD Study
Praxis Precision Medicines Inc. announced clinical updates at the American Epilepsy Society Annual Meeting on December 6, 2025, highlighting positive results from the EMBOLD study of relutrigine in patients with developmental and epileptic encephalopathies (DEEs). The results, already presented at the meeting, showed a 53% placebo-adjusted reduction in seizures and a 66% increase in motor seizure-free days over 16 weeks. Clinician and caregiver assessments indicated statistically significant improvements in alertness, communication, and seizure severity. Praxis stated that it will meet with the FDA to discuss next steps for a potential New Drug Application (NDA) for relutrigine and will determine NDA filing timing following the meeting. The company also reported completion of recruitment for the POWER1 pivotal study in focal onset seizures (FOS), with additional studies planned or ongoing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598347-en) on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.